Donor CAR T cells targeting CD19 and CD22 to prevent relapse in adult B‑ALL
Official title: Donor Derived CD19/CD22 CAR T Cells as Concurrent Therapy Against Relapse in Adults with B-ALL
Funded at Stanford University · NIH-11197508 · Data updated 2026-11-12
Adults with B‑cell acute lymphoblastic leukemia receive a donor stem‑cell transplant with regulatory T cells followed by donor CAR T cells that target CD19 and CD22 to try to lower the chance the leukemia comes back.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project start | May 1, 1997 |
| Project end | August 31, 2030 |
| Funding year | 2025 |
| Award (this year) | $465,085 |
| NIH project number | 2P01CA049605-34A1 |
| Project ID | NIH-11197508 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are adults (21+) with B‑cell acute lymphoblastic leukemia who are planned for or eligible to receive an allogeneic stem‑cell transplant and meet clinical criteria for post‑transplant donor CAR T cell therapy.
✕Less likely to help
Children, people with non‑B‑ALL cancers, those not eligible for allogeneic transplant, or individuals with uncontrolled medical issues or infections are unlikely to benefit from this specific program.
What this research studies
You would receive an allogeneic stem‑cell transplant that includes purified regulatory T cells, CD34+ stem cells, and conventional T cells to help prevent graft‑versus‑host disease. After the transplant, you would get a consolidative dose of donor‑derived CAR T cells engineered to recognize both CD19 and CD22 on B cells. The project is being run as a phase I, single‑center program at Stanford and includes laboratory correlative studies and supporting preclinical work. The goal is to see whether combining Treg‑enriched grafts with donor CAR T cells can reduce relapse while keeping GVHD manageable.
Why it matters
Potential benefit: If successful, this approach could lower relapse rates after donor transplant and help more adults with B‑ALL achieve longer remissions with controllable GVHD.
How similar studies have gone: Autologous CD19/CD22 CAR T therapies have produced remissions but many patients relapsed, and preliminary data indicate donor‑derived CAR T cells after transplant may cause less GVHD, so this combined approach is relatively new and is being tested.
Where this research is happening
-
Stanford University
Stanford, United States Active
Researchers
- Principal investigator: Miklos, David B. — Stanford University
- Study coordinator: Miklos, David B.
Related research
Other NIH-funded projects on the same topics.
-
Metabolic drivers of B-ALL diversity and relapse risk
A study at Stanford will explore how diverse B-cell receptor rearrangements and their metabolism shape relapse risk in children and adults with B-ALL, with the goal of improving detection and treatment.
-
Donor CAR T Cells Added to Transplant to Prevent Relapse in adults with B-ALL
A new approach combines donor CAR-T cells targeting CD19 and CD22 with a stem cell transplant to lower relapse risk in adults with B-ALL.
-
Social stress and smoking: why disadvantaged young adults struggle to quit
This grant looks at how daily social stress affects if and when disadvantaged young adults who smoke can quit and stay quit.
-
Learning from remission and relapse in lupus (SLE)
Researchers are studying people with systemic lupus erythematosus who are in long-term remission without steroids or immunosuppressants to understand their immune cells, brain function, and what might predict relapse.
-
Learning from Remission and Relapse in SLE
A program to study people with systemic lupus erythematosus who are in long-term remission to understand immune and brain signals that might predict relapse.
-
Alternative NF-kB activation after chemotherapy in ovarian cancer
This grant studies how ovarian cancer might come back after chemotherapy by looking at specific signaling pathways in cancer cells and the tumor environment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.